FDA peptide warning: what the 503A list changes actually mean
The FDA's recent changes to the 503A compounding list confused a lot of buyers. Here's what actually changed and what it means in practice.
by Editorial team
What the 503A list is
Section 503A of the Federal Food, Drug, and Cosmetic Act governs which substances licensed compounding pharmacies in the US can compound for patient use. The FDA periodically reviews and updates the list of substances eligible for compounding.
When a peptide is removed from or excluded from the 503A list, licensed pharmacies can no longer legally compound it for human use in the US.
Recent changes
BPC-157, several growth-hormone-related peptides, and a handful of others have been excluded from the eligible list in recent FDA actions. The FDA cited insufficient safety data and quality concerns.
This change does not make personal research-use sales illegal — but it does mean US compounding pharmacies can no longer prescribe and compound these peptides for patients.
What it means for buyers
If you were getting peptides through a US clinic or compounding pharmacy, your access may have changed. If you were buying research-use peptides from overseas or specialty vendors, the legal landscape for your purchase is similar to before — though customs scrutiny has increased.